Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The U.S. Food and Drug Administration has its hands full making sure medical AI products are safe, efficacious and trustworthy before they hit the market. The rise of ever-more-innovative iterations of the technology—not least generative AI—is only adding to the burden.
Among AI’s most watchful stakeholders are healthcare organizations in need of AI talent and AI talent in need of work in healthcare. Both groups need to keep up with the technology in its present as well as future iterations.
Dynocardia has now received nearly $5.1 million in funding from the NHLBI to help speed commercializing its wrist-worn monitor to avoid the need for invasive catheter BP monitoring.
Timothy Story, MD, said Ascension St. Vincent Medical Center damaged his career and reputation after they fired him without cause. After a three-and-a-half year legal trial, a jury in Indiana agreed.
Welcome to Movers & Shakers, a roundup of the latest executive movements in the healthcare space, featuring Johnson & Johnson, Community Healthcare Trust and Emids.
Healthcare and public health organizations have been alerted to another ransomware threat––this time from the Democratic People’s Republic of Korea (DPRK).
The latest findings highlight the worsening crisis of burnout among U.S. clinicians, who have frequently cited the COVID-19 pandemic as a major impact.
Johnson & Johnson has discontinued its Mosaico clinical trial that aimed to protect against HIV after its Phase 3 study revealed the regiment was safe but ineffective.
Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.
When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.
If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation.